Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

October 15, 2015 Leave a comment 2,800 Views

GHENT, Belgium, October 15, 2015 – Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Isis Pharmaceuticals

Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

The MAQC Society announces publication of a collection of next-gen sequencing best practice articles

New research provides useful genetic resource on farm-raised kuruma shrimp

Rutgers neurologist explores link between COVID and ‘Brain Fog,’ dementia with MRI and RNA sequencing

Upcoming Webinar – Impact of SARS-CoV-2 Infection on Host Gene Expression Across Multiple Tissues at Single Cell Resolution

Tissue heterogeneity as a widespread phenomenon in publicly available gene expression datasets

The eQTL Catalogue – a compendium of uniformly processed human gene expression and splicing quantitative trait loci

The Spatial Mouse Atlas: new insights into cell fate